Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RebmAb300
- Development stage
- Preclinical
- Lead developer
- Recepta Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RebmAb300 is a humanized monoclonal antibody developed by Recepta Biopharma that targets the Insulin-like Growth Factor 1 Receptor (IGF-1R). IGF-1R is a transmembrane tyrosine kinase receptor that is frequently overexpressed in various solid tumors, where it plays a pivotal role in cell proliferation, survival, and resistance to apoptosis. By binding to the extracellular domain of IGF-1R, RebmAb300 prevents the binding of its ligands, IGF-1 and IGF-2, thereby inhibiting the activation of downstream signaling pathways such as PI3K/Akt and MAPK. This inhibition results in reduced tumor growth and enhanced sensitivity to other therapeutic agents. The antibody was licensed from the Ludwig Institute for Cancer Research (LICR) and is currently in early-stage development for the treatment of cancer.
- Other names
- anti-IGF-1R monoclonal antibodyanti-IGF1R monoclonal antibodyanti-IGF 1R monoclonal antibody
02
Targets
Le^b (Lewis b antigen)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on RebmAb300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RebmAb300.